このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

特発性肺線維症の被験者における吸入トレプロスチニルの有効性と安全性の研究 (TETON-1)

2026年11月18日 更新者:United Therapeutics

特発性肺線維症の被験者における吸入トレプロスチニルの有効性と安全性に関する無作為化、二重盲検、プラセボ対照、第3相試験

Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.

調査の概要

詳細な説明

Study RIN-PF-301 is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.

Efficacy assessments include spirometry (FVC), time to clinical worsening, time to first acute exacerbation of IPF, overall survival, King's Brief Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters.

Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label extension (OLE) study after completing the final study visit.

研究の種類

介入

入学 (実際)

598

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • The University of Alabama at Birmingham
    • Arizona
      • Phoenix、Arizona、アメリカ、85012
        • Arizona Pulmonary Specialists, Ltd.
      • Phoenix、Arizona、アメリカ、85006
        • Banner University Medical Center-Phoenix
      • Phoenix、Arizona、アメリカ、85013
        • St. Joseph's Hospital and Medical Center - Norton Thoracic Institute
      • Tucson、Arizona、アメリカ、85724
        • University of Arizona
    • California
      • La Jolla、California、アメリカ、92037
        • UC San Diego Health
      • Los Angeles、California、アメリカ、90095
        • David Geffen School of Medicine at UCLA
      • Newport Beach、California、アメリカ、92663
        • NewportNativeMD, Inc
      • Orange、California、アメリカ、92868
        • University of California, Irvine
      • Palm Springs、California、アメリカ、92262
        • Palmtree Clinical Research, Inc.
      • Sacramento、California、アメリカ、95817
        • UC Davis Health Medical Center
      • San Francisco、California、アメリカ、94143
        • University of California - San Francisco
      • Stanford、California、アメリカ、94305
        • Stanford University Medical Center
    • Colorado
      • Denver、Colorado、アメリカ、80206
        • National Jewish Health
    • Florida
      • Clearwater、Florida、アメリカ、33765
        • St. Francis Sleep Allergy & Lung Institute
      • Gainesville、Florida、アメリカ、32610
        • University of Florida Health at Shands
      • Jacksonville、Florida、アメリカ、32224
        • Mayo Clinic Florida
      • Jacksonville、Florida、アメリカ、32204
        • Ascension St. Vincent's
      • Jacksonville、Florida、アメリカ、32209
        • University of Florida
      • Kissimmee、Florida、アメリカ、34741
        • Pulmonary Disease Specialists, PA d/b/a PDS Research
      • Orlando、Florida、アメリカ、32803
        • Central Florida Pulmonary Group, PA
      • St. Petersburg、Florida、アメリカ、33704
        • Coastal Pulmonary & Critical Care PLC
      • Tampa、Florida、アメリカ、33606
        • University of South Florida Health
      • Weston、Florida、アメリカ、33331
        • Cleveland Clinic Florida
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Emory University Hospital
      • Atlanta、Georgia、アメリカ、30309
        • Piedmont Healthcare Atlanta
    • Hawaii
      • Honolulu、Hawaii、アメリカ、96813
        • The Queen's Medical Center
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Northwestern Memorial Hospital
      • Chicago、Illinois、アメリカ、60612
        • Rush University Medical Center Outpatient Pulmonary Clinic
      • Maywood、Illinois、アメリカ、60153
        • Loyola University Medical Center
    • Indiana
      • Indianapolis、Indiana、アメリカ、46250
        • Community Health Network
    • Kansas
      • Kansas City、Kansas、アメリカ、66160
        • The University of Kansas Medical Center
    • Kentucky
      • Louisville、Kentucky、アメリカ、40202
        • University of Louisville
      • Louisville、Kentucky、アメリカ、40202
        • Norton Pulmonary Specialists
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70112
        • Tulane University Medical Center
      • New Orleans、Louisiana、アメリカ、70112
        • LSU Health Sciences Center New Orleans
      • Shreveport、Louisiana、アメリカ、71103
        • LSU Health Science Center Shreveport
    • Maryland
      • Baltimore、Maryland、アメリカ、21224
        • Johns Hopkins Asthma & Allergy Center
      • Silver Spring、Maryland、アメリカ、20904
        • Adventist Healthcare White Oak Medical CEnter
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • Brigham and Women's Hospital
      • Boston、Massachusetts、アメリカ、02114
        • Massachusetts General Hospital
      • Boston、Massachusetts、アメリカ、02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • University of Michigan Int Med Pulmonary and critical care
      • Detroit、Michigan、アメリカ、48202
        • Henry Ford Hospital
      • Royal Oak、Michigan、アメリカ、48073
        • Corewell Health William Beaumont Hospital
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55455
        • University of Minnesota
      • Rochester、Minnesota、アメリカ、55902
        • Mayo Clinic
    • Mississippi
      • Jackson、Mississippi、アメリカ、39216
        • University of Mississippi Medical Center
    • Missouri
      • Chesterfield、Missouri、アメリカ、63017
        • The Lung Research Center
      • Kansas City、Missouri、アメリカ、64111
        • Saint Luke's Hospital of Kansas City
      • St Louis、Missouri、アメリカ、63110
        • Washington University School of Medicine
    • Nebraska
      • Omaha、Nebraska、アメリカ、68124
        • Creighton University Clinical Research Office
    • New Mexico
      • Albuquerque、New Mexico、アメリカ、87106
        • University of New Mexico Health Sciences Center
    • New York
      • Commack、New York、アメリカ、11725
        • Stony Brook Advanced Specialty Care
      • Liverpool、New York、アメリカ、13088
        • St Joseph's Physician's Pulmonary Health
      • New Hyde Park、New York、アメリカ、11040
        • Northwell Health
      • Rochester、New York、アメリカ、14642
        • University of Rochester Medical center
      • The Bronx、New York、アメリカ、10467
        • Montefiore Medical Center
    • North Carolina
      • Greensboro、North Carolina、アメリカ、27403
        • PulmonIx, LLC
      • Greenville、North Carolina、アメリカ、27834
        • East Carolina University and Leo Jenkins Cancer Center
      • Winston-Salem、North Carolina、アメリカ、27103
        • Southeastern Research Center
    • Ohio
      • Cincinnati、Ohio、アメリカ、45267
        • University of Cincinnati
      • Cleveland、Ohio、アメリカ、44195
        • Cleveland Clinic
      • Columbus、Ohio、アメリカ、43221
        • The Ohio State University Wexner Medical Center - Martha Morehouse Medical Pavilion
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland、Oregon、アメリカ、97220
        • The Oregon Clinic, PC
    • Pennsylvania
      • Hershey、Pennsylvania、アメリカ、17033
        • Penn State Milton S. Hershey Medical Center/Penn State College of Medicine
      • Philadelphia、Pennsylvania、アメリカ、19104
        • University of Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19140
        • Temple Lung Center
      • Philadelphia、Pennsylvania、アメリカ、19107
        • Thoams Jefferson,Hospital University
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • Medical University of South Carolina
      • Columbia、South Carolina、アメリカ、29203
        • Prisma Health Midlands
      • Rock Hill、South Carolina、アメリカ、29732
        • Clinical Research of Rock Hill
    • Tennessee
      • Knoxville、Tennessee、アメリカ、37919
        • Statecare Pulmonary Consultants
      • Nashville、Tennessee、アメリカ、37204
        • Vanderbilt University Medical Center
    • Texas
      • Dallas、Texas、アメリカ、75246
        • Baylor University Medical Center
      • Dallas、Texas、アメリカ、75390-8550
        • Univrsity of Texas Southwestern Medical Center
      • Denison、Texas、アメリカ、75020
        • Premier Pulmonary Critical Care and Sleep Medicine
      • Houston、Texas、アメリカ、77030
        • The University of Texas Health Science Center at Houston
      • Houston、Texas、アメリカ、77030
        • Baylor Clinic-Baylor College of Medicine
      • McAllen、Texas、アメリカ、78503
        • A & A Research Consultants, LLC
      • McKinney、Texas、アメリカ、75069
        • Metroplex Pulmonary and Sleep Center PA
      • The Woodlands、Texas、アメリカ、77380
        • Renovatio Clinical Consultants, LLC
    • Utah
      • Murray、Utah、アメリカ、84107
        • Intermountain Medical Center
      • Salt Lake City、Utah、アメリカ、84108
        • University of Utah Health
    • Virginia
      • Charlottesville、Virginia、アメリカ、22903
        • University of Virginia Health System
      • Falls Church、Virginia、アメリカ、22042
        • Inova Fairfax Hospital
      • Richmond、Virginia、アメリカ、23230
        • Pulmonary Associates of Richmond, Inc.
    • Wisconsin
      • Madison、Wisconsin、アメリカ、53792
        • University of Wisconsin School of Medicine and Public health
      • Milwaukee、Wisconsin、アメリカ、53226
        • Medical College of Wisconsin
    • British Columbia
      • Vancouver、British Columbia、カナダ、V6Z1Y6
        • St.Paul's Hospital
    • Ontario
      • Ajax、Ontario、カナダ、L1S 2J5
        • Dynamic Drug Advancement Limited
      • Hamilton、Ontario、カナダ、L8N 4A6
        • St. Joseph's Healthcare Hamilton
      • Toronto、Ontario、カナダ、M5G 2C4
        • Toronto General Hospital
    • Quebec
      • Québec、Quebec、カナダ、G1V 4G5
        • Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite
      • Trois-Rivières、Quebec、カナダ、G8T 7A1
        • Centre d'investigation Clinique Mauricie

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

40年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Subject gives voluntary informed consent to participate in the study.
  2. Subject is ≥40 years of age, inclusive, at the time of signing informed consent.
  3. The subject has a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline (Raghu 2018) and confirmed by central review of high-resolution computed tomography (HRCT) (performed within the previous 12 months), and if available, surgical lung biopsy.
  4. FVC ≥45% predicted at Screening.
  5. Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for ≥30 days prior to Baseline. Concomitant use of both pirfenidone and nintedanib is not permitted.
  6. Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will abstain from intercourse (when it is in line with their preferred and usual lifestyle) or use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.
  7. Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
  8. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.

Exclusion Criteria:

  1. Subject is pregnant or lactating.
  2. Subject has primary obstructive airway physiology: FEV1/FVC <0.70 at Screening.
  3. The subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
  4. The subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), or soluble guanylate cyclase stimulators within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours of any study-related efficacy assessments.
  5. Use of any of the following medications: azathioprine (AZA), cyclosporine, mycophenolate mofetil, tacrolimus, oral corticosteroids (OCS) >20 mg/day or the combination of OCS+AZA+N-acetylcysteine within 30 days prior to Baseline; cyclophosphamide within 60 days prior to Baseline; or rituximab within 6 months prior to Baseline.
  6. The subject is receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
  7. Exacerbation of IPF or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of IPF or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.
  8. Uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.
  9. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.
  10. Use of any other investigational drug/device or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication/supplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.
  11. Life expectancy <6 months due to IPF or a concomitant illness.
  12. Acute pulmonary embolism within 90 days prior to Baseline.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Placebo

Matching placebo inhaled using an ultrasonic nebulizer QID

Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

Placebo administered QID

実験的:Inhaled Treprostinil

Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.

Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

Inhaled treprostinil (6 mcg/breath) administered QID

他の名前:
  • ティバソ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Absolute FVC From Baseline to Week 52
時間枠:Baseline to Week 52

The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.

Baseline to Week 52

二次結果の測定

結果測定
メジャーの説明
時間枠
Time to Clinical Worsening
時間枠:Baseline to Week 52

Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

Baseline to Week 52
Time to First Acute Exacerbation of IPF
時間枠:Baseline to Week 52

An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

Baseline to Week 52
Overall Survival at Week 52
時間枠:Week 52

Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).

Week 52
Change in % Predicted FVC From Baseline to Week 52
時間枠:Baseline to Week 52

The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.

Baseline to Week 52
Change in K-BILD Questionnaire Score From Baseline to Week 52
時間枠:Baseline to Week 52

The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.

Baseline to Week 52
Change in DLCO From Baseline to Week 52
時間枠:Baseline to Week 52

The DLCO measurement measures how well oxygen moves from the lungs to the blood.

Baseline to Week 52

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年4月21日

一次修了 (実際)

2026年2月2日

研究の完了 (実際)

2026年2月2日

試験登録日

最初に提出

2021年1月12日

QC基準を満たした最初の提出物

2021年1月12日

最初の投稿 (実際)

2021年1月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月18日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • RIN-PF-301

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する